BioSpace News Archive

Senhwa Biosciences, Inc. announced today that Taiwan FDA has approved its Phase II IND application of Silmitasertib(CX-4945) to treat hospitalized patients with moderate to severe COVID-1.

Agile Therapeutics, Inc., a women’s healthcare company, announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive preliminary results from the Phase 1a dose-escalation component of its ongoing ADVANCED-1 clinical trial of TARA-002, the Company’s investigational cell-based therapy, for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC).

Tyber Medical LLC, the global leader in private-label medical devices for major orthopedic trauma, extremity, and spine companies, announced the expansion of its Florida facility by 33,000 square feet.

Is there a link between Agent Orange and bladder cancer? Do automobile mechanics, shoemakers and painters have a higher risk of bladder cancer? Can your bladder cancer get worse by smoking?

Is kidney stone information on TikTok reliable? Is alkaline water better than tap water for uric acid stone patients? Do videos on social media align with AUA recommendations?

Astria Therapeutics, Inc. today announced that it will present information on STAR-0215 and its development in two presentations at the 13th C1-Inhibit Deficiency and Angioedema Workshop in Budapest, Hungary.

Avinger, Inc. today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England.

GeneDx today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company’s Class A common stock.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive headline results of a phase 2a trial in the treatment of hypertrophic scars which met the primary observer-based endpoint at week 24 as evaluated by the Patient and Observer Scar Assessment Scale (POSAS).